NeoGenomics: David Eberhard

NeoGenomics has appointed David Eberhard as chief medical officer of Inivata, NeoGenomics' liquid biopsy-focused subsidiary. Eberhard will be in charge of the clinical and strategic development of the subsidiary's liquid biopsy tests, including the RaDaR test for minimal residual disease. He most recently served as senior medical director of oncology at Illumina and was previously the senior director of oncology development at Genomic Health, focusing on bringing the firm's OncotypeSEQ liquid biopsy test to market.